Company Overview

Shire Human Genetic Therapies Inc., a biopharmaceutical company, develops, and commercializes therapeutics for the treatment of genetic diseases caused by protein deficiencies. It markets and sells Replagal, an enzyme replacement therapy for the long-term treatment of patients with Fabry disease, in 34 countries outside the United States. The company’s primary clinical programs include iduronate-2-sulfatase, an enzyme replacement therapy for the treatment of hunter syndrome, which is in phase III clinical trials; and Gene-Activated glucocerebrosidase, an enzyme replacement therapy for the treatment of Gaucher disease, which is in phase I/ II clinical trials. In addition, Shire Human Genetic ...

Shire Human Genetic Therapies Inc., a biopharmaceutical company, develops, and commercializes therapeutics for the treatment of genetic diseases caused by protein deficiencies. It markets and sells Replagal, an enzyme replacement therapy for the long-term treatment of patients with Fabry disease, in 34 countries outside the United States. The company’s primary clinical programs include iduronate-2-sulfatase, an enzyme replacement therapy for the treatment of hunter syndrome, which is in phase III clinical trials; and Gene-Activated glucocerebrosidase, an enzyme replacement therapy for the treatment of Gaucher disease, which is in phase I/ II clinical trials. In addition, Shire Human Genetic Therapies, in collaboration with Aventis Pharmaceuticals, Inc., developed Dynepo, a human erythropoietin for the treatment of anemia related to chronic renal failure. The company was founded in 1988 and is headquartered in Cambridge, Massachusetts. As of July 27, 2005, Shire Human Genetic Therapies Inc. operates as a subsidiary of Shire plc.

Key Executives for Shire Human Genetic Therapies Inc.

Similar Private Companies By Industry

Recent Private Companies Transactions